Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer

Journal of Nuclear Medicine

Volumn 39, Issue 3, 1998, Pages 459-464

  Taillefer, Raymond ^a   Robidoux, André ^a   Turpin, Sophie ^a   Lambert, Raymond ^a   Cantin, Jacques ^a   Léveillé, Jean ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Axillary lymph nodes; Breast cancer; Technetium 99m MIBI

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CONTRAST ENHANCEMENT; DATA ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS;

AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI;

EID: 0031929826     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Pollei SR, Mettler FA, Bartow SA, Moradian G, Moskowitz M. Occult breast cancer: prevalence and radiographic detectability. Radiology 1987;163:459-462.
2. Moskowitz M, Gartside PS. Evidence of breast cancer mortality reduction: aggressive screening in women under age of 30. Am J Roentgenol 1982;138:911-916.
3. Shapiro S, Venet W, Strax P. Ten-to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982;69:349-355.
4. Habbema JDF, van Oortmarssen GV, van Putten DJ, Lubbe JT, van der Maas PJ. Age-specific reduction in breast cancer mortality by screen: an analysis of the results of Health Insurance Plan of greater New York study. J Natl Cancer Inst 1986;77:317-320.
5. Homer MJ. Nonpalpable breast abnormalities: a realistic review of the accuracy of mammography in detecting malignancies. Radiology 1984;153:831-832.
6. Rodes N, Lopez M, Pearson D. The impact of breast cancer screening on survival: a 5-to 10-year follow-up study. Cancer 1986;57:581-585.
7. Taba R, Faberberg C, Grad A. Reduction in mortality from breast cancer after mass screening with mammography: randomized trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985;1:829-832.
8. Jones BA, Kasl S V, Curnen MGM, Owens PH, Dubrow R. Can mammography screening explain the race difference in stage at diagnosis of breast cancer? Cancer 1995;75:2103-2113.
9. Coveney EC, Geraghty JG, O'laoide R, Hourihane JB, O'higgins NJ. Reasons underlying negative mammography in patients with palpable breast cancer. Clin Radiology 1994;49:123-125.
10. Helvie MA, Joynt LK, Cody RL, et al. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology 1996;198:327-332.
11. Meyer JE, Sonnenfeld MR, Greenes RA, Stomper PC. Preoperative localization of clinically occult breast lesions: experience at a referral hospital. Radiology 1988;169: 627-628.
12. Spivey GH, Perry BW, Clark VA, Coulson AH, Coulson WF. Predicting the risk of cancer at the time of biopsy: variation in the benign to malignant ratio. Am Surg 1982;48:326-332.
13. Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomography imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992;216:27-34.
14. Chaiken L, Rege S, Hoh C, et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:455-464.
15. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71:3920-3925.
16. Say C, Donegan W. A biostatistical evaluation of complications from mastectomy. Surg Gynecol Obstet 1974;138:370-375.
17. Uren RF, Howman-Giles RB, Thompson JF, et al. Mammary lymphoscintigraphy in breast cancer. J Nucl Med 1995;36:1775-1780.
18. Alazraki N. Lymphoscintigraphy and the intraoperative gamma probe (editorial). J Nucl Med 1995;36:1780-1783.
19. Schatten C, Barrada M, Mandeville R, et al. Combined use of 123I-labeled BCD-F9 and 4C4 monoclonal antibody with dissimilar specificity for breast cancer: implication for the detection limit of immunolymphoscintigraphy in the assessment of axillary lypmh node metastases. Nucl Med Commun 1994;15:422-429.
20. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with (F-18) 2-deoxy-2-fluoro-d-glucose PET. Radiology 1993; 187:743-750.
21. Turoglu HT, Janjan NA, Thorsen MK, et al. Imaging of regional spread of breast cancer by internal mammary lymphoscintigraphy, CT and MRI. Clin Nucl Med 1992;6:482-484.
22. Kairemo KJ. Immunolymphoscintigraphy with 99mTc-labeled monoclonal antibody (BW 431/26) reacting with carcinoembryonic antigen in breast cancer. Cancer Research 1990;50:949s-954s.
23. Khalkhali I, Mena I, Jouanne E, et al. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg 1994;178:491-497.
24. Khalkhali I, Mena I, Diggles L. Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi. Eur J Nucl Med 1994;21:357-362.
25. Kao CH, Wang SJ, Yeh SH. Technetium-99m-MIBI uptake in breast carcinoma and axillary lymph node metastases. Clin Nucl Med 1994;19:898-900.
26. Taillefer R, Robidoux A, Lambert R, Turpin S, Laperrière J. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995;36:1758-1765.
27. Villanueva-Meyer J, Leonard MH, Briscoe E, et al. Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer. J Nucl Med 1996;37:926-930.
28. Palmedo H, Schonburg A, Grunwald F, Mallmann P, Krebs D, Biersack HJ. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med 1996;37:626-630.
29. 201T1 in unsuspected breast tumor. Clin Nucl Med 1992;17:936-937.
30. 99mTc-sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995;196:421-426.
31. 99mTc-methoxy isobutyl isonitrile (MIBI) in the evaluation of patients with primary carcinoma of the breast. Clin Nucl Med 1992;9:761.
32. Khalkhali I, Cutrone J, Mena I, et al. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med 1995;36:1784-1789.
33. Lam WWM, Yang WT, Stewart IET, Metreweli C, King W. Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound and conventional mammography. Eur J Nucl Med 1996;23: 498-503.
34. Gagnon A, Taillefer R, Bavaria G, Léveillé J. Fast labeling of technetium-99m-sestamibi with microwave oven heating. J Nucl Med Technol 1992;19:90-93.
35. Danforth DD, Lippman ME. Surgical treatment of breast cancer. In: Diagnosis and management of breast cancer. Philadelphia: Saunders; 1988:95-155.
36. Maublant J, de Latour M, Mestas D, et al. Technetium-99m-sestamibi uptake in breast tumor and associated lymph nodes. J Nucl Med 1996;37:922-925.
37. Nagaraj N, Waxman A, Ashok G, et al. Comparison of SPECT and planar Tc-99m sestamibi (MIBI) imaging in patients with carcinoma of the breast [Abstract]. J Nucl Med 1994;35:229P.
38. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-1822.